EUNETWORKS
6.12.2022 09:46:41 CET | Business Wire | Press release
euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced that its Board of Directors has agreed to the appointment of Paula Cogan as its Chief Executive Officer, effective 1 January 2023. Paula currently holds the position of President, euNetworks. Paula will succeed CEO Brady Rafuse, who will become Chairman of euNetworks’ Board of Directors, with the existing Chairman Neil Hobbs remaining on the Board of Directors as a Non Executive Director.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221206005159/en/
Paula Cogan, euNetworks (Photo: Business Wire)
Paula is currently President, euNetworks, with responsibility for all operating aspects of the business. She joined euNetworks in November 2021, building on her 30 years of working in the telecoms industry. She has held various senior leadership positions in companies such as British Telecom, Verizon and Colt. Prior to joining euNetworks Paula was most recently Executive Vice President – Sales, Marketing and Customer Relationship Management at Colt, responsible for the commercial strategy of the business. Throughout her career Paula has been known for driving transformation in both teams and organisations, leading global sales, marketing, engineering and commercial teams as well as building successful channel strategies. With a strong track record in people management and mentoring, she is committed to promoting and driving inclusion and diversity within the telecoms Industry.
“I am excited to lead this exceptional and high-performing team of people through the next chapter of euNetworks’ growth,” said Paula Cogan. “euNetworks continues to distinguish itself in the digital infrastructure ecosystem, delivering critical internet infrastructure to customers. It’s an asset rich business, focused on developing and deepening its fibre networks, innovating and investing in new technologies to deliver highly scalable, owned and operated fibre-based and sustainable infrastructure in Europe. The vision that Brady and the team have followed and delivered creates an exciting opportunity for us all as we continue to drive the business forward. I want to thank Brady for that and also for his continued support as Chairman as we move forward in 2023.”
Brady joined euNetworks in March 2009. He has led euNetworks through its delisting on the Singapore Stock Exchange, privatisation with Columbia Capital, and sale to Stonepeak, with increased investment from IMCO. The business has become a critical bandwidth infrastructure company supporting Europe’s future bandwidth needs and a portfolio of customers who are the fastest growing consumers of bandwidth under his leadership. Brady has guided the company to become the leading data centre to data centre connectivity provider in Europe, with a unique set of connectivity options in both its metro and long haul network, including the development of Super Highways and new subsea cables. This has enabled the company to deliver exceptional growth and success, underpinned by a team with collective company values and a focus on the belief that bandwidth changes everything.
“I’m immensely proud of the team and it has been a privilege working with them as well as our investors, customers, partners and with the communities that we operate in across Europe,” said Brady Rafuse. “Paula is an exceptional leader. Her achievements in her career have been underpinned by her ability to foster strong relationships with customers and partners whilst remaining focused on leading organisations and people. Paula joined the euNetworks team a year ago and since then we have been working closely to ensure a smooth transition as we move forward with our plans and continue to grow the business. With Paula’s focus over the last year on all operating aspects of the business and her customer-centric approach, she has already made a great contribution to our performance in 2022 and I am excited for the company’s future with Paula as CEO. Thank you to Neil for his support, contribution and guidance since joining the euNetworks Board of Directors in January 2014. His extensive and global board and management experience has been hugely valuable to us all during his time as Chairman on our Board.”
“We know Paula is a fantastic leader and, like Brady, has a clear vision to guide euNetworks as we progress with growth plans for the business,” said Cyrus Gentry, Managing Director and Head of Communications, Europe at Stonepeak. “euNetworks is the fastest growing fibre business in Europe. It has a highly differentiated network platform that underpins the digital infrastructure ecosystem and there remains no shortage of compelling capital opportunities in Europe for euNetworks to further build on the unique position it has in the region. We extend our thanks to Brady for everything he has delivered as CEO, and we look forward to the value he will continue to deliver as Chairman.”
About euNetworks
euNetworks is a critical bandwidth infrastructure company, owning and operating 17 fibre based metropolitan networks connected with a high capacity intercity backbone covering 53 cities in 17 countries across Europe. The company leads the market in data centre connectivity, directly connecting over 490 today. euNetworks is also a leading cloud connectivity provider and offers a targeted portfolio of metropolitan and long haul services including Dark Fibre, Wavelengths, and Ethernet. Wholesale, finance, content, media, mobile, data centre and enterprise customers benefit from euNetworks’ unique inventory of fibre and duct based assets that are tailored to fulfil their high bandwidth needs. For further information visit eunetworks.com.
About Stonepeak
Stonepeak is a leading alternative investment firm specializing in infrastructure and real assets with approximately $51.7 billion of assets under management. Through its investment in defensive, hard-asset businesses globally, Stonepeak aims to create value for its investors and portfolio companies, and to have a positive impact on the communities in which it operates. Stonepeak sponsors investment vehicles focused on private equity and credit. The firm provides capital, operational support, and committed partnership to sustainably grow investments in its target sectors, which include communications, energy transition, transport and logistics, and social infrastructure. Stonepeak is headquartered in New York with offices in Austin, Hong Kong, Houston, London and Sydney. For more information, please visit www.stonepeak.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221206005159/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom